secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001171843-26-002103
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose shareholders approve Hanmi go-private at C$2.41/share; FY net loss $25.5M
--------------------------------------------------------------------------------

- Shareholders approved acquisition by Hanmi at C$2.41/share (28% premium over 30-day VWAP of C$1.88).
- 84.87% of non-Hanmi shares voted for the arrangement; Alberta court issued final order; closing expected by end of April 2026.
- FY2025 net loss $25.5M (flat vs $25.4M); cash $4.1M as of Dec 31, 2025; company notes insufficient cash to fund operations; relies on Hanmi advances.
- TUS+VEN+AZA triplet in newly diagnosed AML showed 90% CR/CRh, 78% MRD negativity by central flow; no dose-limiting toxicities.
- Hanmi provided over US$41M in debt facilities over past 18 months to support Aptose.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184326002103/0001171843-26-002103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184326002103/f8k_033126.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-002103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer